Persister cells are a small fraction of any bacterial population that survive antibiotic treatment not by resisting the drug, but by essentially shutting down the cellular machinery the drug needs to work. They are genetically identical to their susceptible neighbors, carry no resistance mutations, and would be killed by the same antibiotic if they were metabolically active. But because they enter a dormant or near-dormant state, antibiotics pass over them the way a pesticide fails to kill a hibernating insect. Once treatment stops, these survivors wake up, resume growing, and can reignite an infection that appeared to be cured. The phenomenon sits at the intersection of microbiology, evolution, and clinical medicine, and understanding it changes how we think about treatment failure.
What Makes a Persister Cell Different from a Resistant One
The distinction between persistence and resistance is fundamental and often confused. A resistant bacterium has acquired a genetic change, either through mutation or by picking up new DNA from another microbe, that lets it grow and divide even while the antibiotic is present. Its offspring inherit that change. Resistance is permanent and heritable, and it raises the minimum drug concentration needed to stop growth. Persister cells, by contrast, tolerate antibiotics through temporary physiological changes. Their susceptibility to the drug is unchanged in laboratory terms; if you took a persister cell, woke it up, and re-exposed it to the same antibiotic, it would die just like its siblings. Persistence is not written into the genome. It is a reversible state that a small subpopulation enters, often stochastically.
1Journal of Pure and Applied Microbiology. Bacterial Dormancy and Persister Cells: Molecular Insights and Clinical Implications for Antimicrobial Resistance – A Narrative ReviewThis matters clinically because the standard response to resistant bacteria is to switch to a different drug. But switching drugs does not help against persisters, because persisters are not growing in the first place. Most antibiotics work by corrupting active processes: building cell walls, copying DNA, assembling proteins. A cell that has paused those processes simply has fewer targets for the drug to sabotage. The implication is that persistence demands a fundamentally different therapeutic strategy from resistance, one that either wakes the dormant cells up so conventional drugs can kill them, or kills them through mechanisms that do not require active metabolism.
The Molecular Machinery Behind Dormancy
Several interconnected molecular systems push a bacterial cell into the persister state. One of the most studied involves toxin-antitoxin modules, pairs of genes where one encodes a protein that inhibits growth and the other encodes a counteracting molecule that neutralizes it. Under normal conditions, the antitoxin keeps the toxin in check. But if the balance tips, perhaps because the antitoxin degrades faster under stress, the toxin accumulates and shuts down key processes like protein synthesis or DNA replication, effectively putting the cell to sleep. In the model organism E. coli, deleting certain toxin-antitoxin gene pairs significantly reduces the number of persister cells a population can produce.
2PubMed. Bacterial persistence and toxin-antitoxin lociSingle-cell analysis has revealed that the ratio between toxin and antitoxin levels within individual cells matters enormously. Researchers have demonstrated that bacteria elevate this ratio through distinct expression patterns when facing antibiotic challenge, with a toxin-to-antitoxin ratio of about 1.0 acting as a critical threshold for entering the persister state.
3PubMed Central. Single-cell analysis reveals critical toxin/antitoxin ratio triggering persister resuscitationRunning alongside the toxin-antitoxin system is a stress-signaling molecule called ppGpp, sometimes nicknamed the “magic spot.” Nearly all bacteria produce it when they face starvation or environmental stress. ppGpp orchestrates a sweeping slowdown called the stringent response: protein production drops, growth halts, and the cell hunkers down. When the two genes in E. coli responsible for making ppGpp are deleted, persister cells become extremely rare in actively growing cultures.
4Cell. Molecular mechanisms underlying bacterial persisters – Section: Signaling Pathways behind Induced PersistenceppGpp is not just a starvation alarm. It is also implicated in bacterial pathogenesis and host invasion, which means the same molecule that helps bacteria survive inside a stressed body also primes them for dormancy when antibiotics arrive.
5PubMed Central. (p)ppGpp and Its Role in Bacterial Persistence: New ChallengesBeneath both of these systems lies something even more basic: cellular energy. Persisters tend to have depleted ATP levels, and that energy drop appears to be a major driver of the dormant state rather than just a side effect. Lower ATP slows down the protein-making machinery, prevents the kind of DNA damage that certain antibiotics rely on to kill cells, and generally makes the cell a harder target. Researchers have shown that artificially lowering ATP in E. coli directly causes drug tolerance, and that random variation in ATP levels across a population is a primary mechanism by which some cells become persisters in the first place.
6PubMed Central. ATP-Dependent Persister Formation in Escherichia coliATP depletion also promotes the formation of protein aggregates inside the cell, collections of clumped-up proteins that serve as a marker of how deeply dormant a bacterium has become. The deeper the dormancy, the larger these aggregates, and the more resilient the cell is to killing.
7Molecular Cell. Persister Cells: Insights on Mechanisms and Clinical ImpactThe Evolutionary Logic of Sleeping Through Danger
Producing persister cells is costly for a bacterial population. The cells that go dormant stop reproducing, which means they fall behind in the evolutionary race during good times. So why does the trait persist? The answer lies in a concept called bet-hedging, a risk-spreading strategy where a genetically identical population randomly diversifies its behavior so that some individuals are prepared for catastrophe even if most are optimized for current conditions.
8PubMed Central. Diversity of bet-hedging strategies in microbial communities-Recent cases and insightsThe analogy to financial hedging is striking. Just as a diversified investment portfolio protects against an unpredictable market crash, maintaining a small reserve of non-growing cells protects a bacterial population against an unpredictable antibiotic assault. The “investment” in slow-growing persisters pays off only when disaster strikes, but when it does, the payoff is survival of the lineage.
9PubMed Central. Persistence as an Optimal Hedging StrategyBet-hedging does not require any forecasting on the bacteria’s part. It works purely through stochastic variation: random noise in gene expression causes a few cells in every generation to tip into dormancy. In stable, nutrient-rich environments, those cells are wasted potential. But in the fluctuating, antibiotic-punctuated environments that bacteria actually encounter inside a treated host, they are the population’s insurance policy.
10PubMed. Microbial bet-hedging: the power of being differentSome researchers have proposed that persister cells may also represent a form of evolution through epigenetic inheritance, where the dormancy phenotype is transmitted to daughter cells not through DNA sequence changes but through inherited patterns of gene expression and cellular state. Under this model, the proportion of persisters in a population can evolve over relatively few generations without any genetic mutation, simply through shifts in which epigenetic states are passed along.
11PubMed Central. Interpreting phenotypic antibiotic tolerance and persister cells as evolution via epigenetic inheritanceBiofilms as a Persister Stronghold
Persister cells make up only a tiny fraction of an actively growing bacterial culture, but their proportion climbs dramatically in biofilms, the slimy, surface-attached communities that bacteria form on medical devices, wounds, and body tissues. In biofilms, persister frequency can reach about 1% of the population, orders of magnitude higher than in free-floating cultures.
12PubMed Central. Bacterial persister cell formation and dormancyThe biofilm environment is particularly hospitable to persisters for reasons beyond sheer numbers. The biofilm matrix, a scaffold of sugars, proteins, and DNA that bacteria secrete around themselves, acts as a physical barrier. It slows antibiotic penetration and shields dormant cells from immune cells like neutrophils, which may lack the mechanical force to push through the matrix and reach persisters buried deep inside. Even after antibiotics have killed the majority of cells in a biofilm, the rigid matrix scaffold remains intact, harboring the surviving persisters in a protected niche from which they can regrow and cause a relapse.
13Cell Host & Microbe. Persister Cells: Insights on Mechanisms and Clinical Impact – Section: Tolerance and Persistence in Bacterial BiofilmsThis combination of tolerance to drugs and evasion of immune clearance helps explain why biofilm-associated infections on prosthetic joints, heart valves, and catheters are notoriously difficult to cure with antibiotics alone. The persisters within act as a seed bank, repopulating the biofilm after each treatment cycle.
Recurrent Urinary Tract Infections and Tuberculosis
The clinical footprint of persister cells is most visible in infections that keep coming back despite appropriate antibiotic treatment. Recurrent urinary tract infections are a prime example. They affect roughly 10 to 40% of women, and in up to 77% of recurrent cases, the culprit is the same strain of uropathogenic E. coli that caused the first episode. These bacteria invade bladder lining cells and enter a non-growing, quiescent intracellular state that serves as a reservoir, sheltered from both the immune system and antibiotic courses.
14PubMed Central. Uropathogenic Escherichia coli Metabolite-Dependent Quiescence and Persistence May Explain Antibiotic Tolerance during Urinary Tract InfectionThe persistence mechanisms involved in recurrent UTIs are phenotypic adaptations rather than classical resistance, meaning the bacteria evade treatment and host defenses by changing their behavior, not their genetic code.
15PubMed Central. Mechanisms and clinical implications of bacterial persistence in recurrent urinary tract infectionsThese persisters also contribute to biofilm formation within the urinary tract, creating an additional layer of protection that promotes recalcitrance to treatment.
16PubMed Central. Types I, II, V, and VI secretion system genes in clinical uropathogenic Escherichia coli associate with antibiotic susceptibility, biofilm formation, and persister cellsTuberculosis offers an even more dramatic example. Mycobacterium tuberculosis persists inside granulomas, organized clusters of immune cells that wall off the infection in the lungs. Within these structures, the bacteria encounter low oxygen, acidic pH, nutrient starvation, and oxidative stress, conditions that push them into a non-replicating persistent state. This is why TB treatment requires months of combination therapy: the drugs work quickly against actively growing bacteria but take much longer to clear the dormant population hiding in granulomas.
17PubMed Central. Insights into the molecular determinants involved in Mycobacterium tuberculosis persistence and their therapeutic implications – Section: The granuloma modelPersister cells also modulate how the host immune system responds, contributing not just to treatment failure but to the potential evolution of true genetic resistance over time. A population that survives through persistence buys itself more time and more cell divisions in which resistance mutations can arise.
18PubMed. Impact of bacterial persisters on their hostPersistence Beyond Bacteria
The persister phenomenon is not limited to bacteria. The yeast Candida albicans, a major cause of fungal infections in hospitalized patients, also produces persister cells within biofilms. When Candida biofilms were exposed to the antifungal drug amphotericin B or the antiseptic chlorhexidine, researchers observed a biphasic killing pattern: most cells died rapidly, but a small subpopulation survived even at high drug concentrations. These fungal persisters tolerated both agents simultaneously, making them a multidrug-tolerant subpopulation. Strikingly, persisters were detected only in biofilms, not in free-floating cultures, suggesting that the biofilm environment itself promotes their formation.
19PubMed Central. Candida albicans biofilms produce antifungal-tolerant persister cellsCandida biofilms on indwelling medical devices such as catheters and prosthetic valves are a significant source of hospital-acquired fungal infections, and the presence of persister cells within them helps explain why these infections are so difficult to eradicate and so prone to recurrence.
20Frontiers in Antibiotics. Overcoming Candida biofilm resistance: targeting persister cells with probiotic-derived metabolites – Section: Persister cells in Candida biofilmsThe concept has also been extended to cancer biology. Drug-tolerant persister cells in tumors are a rare subpopulation that survive chemotherapy or targeted therapy through non-genetic adaptive mechanisms. Like their bacterial counterparts, they do not carry resistance mutations but instead enter a reversible state that lets them weather treatment. Once therapy is withdrawn, they can repopulate the tumor and drive relapse. Researchers have found that targeting these cancer persisters with specific inhibitors can delay tumor regrowth.
21Cell Reports Medicine. BET inhibition suppresses drug-tolerant persister cells and delays tumor relapseHow Persisters Wake Up
If persister cells just stayed dormant forever, they would be biologically irrelevant. The clinical threat comes from their ability to resume growth once conditions improve. The resuscitation process is not a simple on-off switch. Single-cell imaging has shown that waking is heterogeneous: some persisters start dividing almost immediately when nutrients return, while others take much longer, and the speed of waking correlates with how many functional ribosomes a cell still has on hand.
22PubMed. Single cell observations show persister cells wake based on ribosome contentThe waking process involves nutrient-sensing receptors on the cell membrane. When nutrients like glucose appear, the cell detects them through chemotaxis receptors and membrane transport systems. This triggers a drop in the intracellular signaling molecule cAMP, which in turn reactivates ribosomes and restarts protein synthesis. Reducing cAMP levels dramatically increases the rate at which persisters wake, and the chemotaxis machinery appears to play a dual role: helping the awakening cell sense and move toward nutrients it needs for recovery.
23iScience. Persister Cells Resuscitate Using Membrane Sensors that Activate Chemotaxis, Lower cAMP Levels, and Revive RibosomesThese details matter therapeutically because they suggest a window of vulnerability. If you could interfere with the resuscitation process, blocking either the nutrient-sensing step or the ribosome reactivation step, you might keep persisters dormant indefinitely or catch them in a fragile transitional state where they become susceptible again.
Therapeutic Strategies Against Persisters
Because conventional antibiotics largely fail against dormant cells, researchers have been exploring fundamentally different approaches. One of the most creative is metabolic potentiation: supplying specific nutrients or carbon sources that restart the cell’s energy-generating machinery, then hitting the now-active cell with an aminoglycoside antibiotic. Aminoglycosides are unusual among antibiotics in that their uptake into the cell depends on the proton motive force, a kind of electrical gradient across the cell membrane that dormant cells lack. Providing metabolic stimulants regenerates that gradient, allowing the drug to flood in and kill the cell even if it has not fully resumed growth.
24PubMed Central. Metabolite-enabled eradication of bacterial persisters by aminoglycosidesThis approach works against both Gram-negative and Gram-positive persisters and is effective under both aerobic and anaerobic conditions, which broadens its potential clinical applicability.
25PubMed Central. Overcoming the energy-dependent barrier to aminoglycoside uptake: multimodal strategies to sensitize Staphylococcus aureus persistersA second strategy sidesteps the need for active metabolism entirely. An experimental antibiotic called ADEP4 hijacks a bacterial enzyme called ClpP, which normally degrades damaged or unneeded proteins in a controlled way. ADEP4 removes ClpP’s selectivity, turning it into an indiscriminate protein-shredding machine that forces the cell to digest itself. Because this self-destruction does not require the cell to be growing or metabolically active, it kills persisters. In a proof-of-concept experiment, combining ADEP4 with the conventional antibiotic rifampicin completely eradicated Staphylococcus aureus biofilms both in lab dishes and in a mouse model of chronic infection.
26PubMed Central. Activated ClpP kills persisters and eradicates a chronic biofilm infectionOther researchers are exploring agents that target the cell envelope directly, structures like the membrane and cell wall that exist regardless of whether the cell is growing. Because these outer structures are always present, drugs that disrupt them do not depend on the metabolic activity that conventional antibiotics require.
27PubMed Central. New Strategies to Kill Metabolically-Dormant Cells Directly Bypassing the Need for Active Cellular ProcessesPhages and Phage-Derived Enzymes
Bacteriophages, viruses that infect bacteria, represent another avenue. Some phages appear capable of inducing metabolic reactivation in dormant cells, coaxing persisters out of their protective state and making them vulnerable. Phage-derived enzymes called endolysins, which chew through the bacterial cell wall from the outside, are particularly interesting because they kill in an enzymatic manner that does not require the cell to be metabolically active. Several endolysins have shown strong activity against biofilms in laboratory settings, and some have outperformed conventional antibiotics in animal models of infections involving biofilm-associated bacteria.
28PubMed. Phage-derived lysins as potential agents for eradicating biofilms and persistersCocktails of multiple phages can be even more effective. In one study against Klebsiella pneumoniae persister cells, a phage cocktail eliminated 99% of persisters and also inhibited the biofilms that persisters tend to seed. Combining the phage cocktail with the aminoglycoside amikacin improved results further, suggesting that phage-antibiotic combinations may be a practical path toward clinical use.
29PubMed Central. Phage vB_KpnM_NB cocktail synergizing with amikacin in inhibiting persister cells of Klebsiella pneumoniaeAdvances in phage engineering, including modifications to improve how well phages recognize their target bacteria and how potently they kill, are expanding the toolkit. Still, clinical translation of phage therapy remains in its early stages, with regulatory frameworks and manufacturing standards still catching up to the science.
30PubMed. Targeting bacterial persistence with bacteriophages: a next-generation antimicrobial strategySeeing Persisters One Cell at a Time
Much of what we know about persister biology has come from studying population averages, but the field is increasingly moving toward single-cell methods that can track what individual bacteria are doing before, during, and after antibiotic exposure. Microfluidic devices coupled with fluorescence microscopy now allow researchers to grow bacteria in precisely controlled micro-channels, add antibiotics, and watch which cells survive and how they behave. Using fluorescent reporters, scientists can monitor stress responses and DNA structure in real time within individual E. coli cells, revealing that the path to becoming a persister is not uniform: cells arrive at dormancy through different routes and wake at different speeds.
31PubMed Central. Single-cell imaging and characterization of Escherichia coli persister cells to ofloxacin in exponential culturesThese single-cell approaches have practical value beyond basic research. If clinicians could one day identify persister-enriched infections early, perhaps through biomarkers related to ribosome content, ATP status, or protein aggregate formation, treatment could be tailored from the start. Instead of waiting for a relapse to suggest that persisters were present, doctors could preemptively apply anti-persister strategies. That remains an aspiration rather than a clinical reality, but the technology to detect and characterize persisters is advancing faster than the therapies to kill them, which at least means the diagnostic side may be ready when effective treatments arrive.